Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 589

1.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

PMID:
20507806
2.

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, Mujica Mota RE.

Pharmacoeconomics. 2017 Mar;35(3):363-373. doi: 10.1007/s40273-016-0453-5. Review.

PMID:
27752999
3.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
4.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.

Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.

PMID:
25444072
5.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
6.

Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review.

PMID:
19911860
7.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

8.

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M.

Health Technol Assess. 2010 May;14 Suppl 1:47-53. doi: 10.3310/hta14Suppl1/07. Review.

9.

The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.

Main C, Pitt M, Moxham T, Stein K.

Health Technol Assess. 2010 Oct;14(Suppl. 2):27-32. doi: 10.3310/hta14suppl2/04. Review.

10.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S.

Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154.

PMID:
28368509
11.

Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2012 May 28;72(8):1111-36. doi: 10.2165/11209430-000000000-00000. Review. Erratum in: Drugs. 2012 Jul 30;72(11):1578.

PMID:
22571445
12.

NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.

Miller W, Holden J, George E, Stein K.

Lancet Oncol. 2011 Apr;12(4):326-7. No abstract available.

PMID:
21598446
13.

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.

Hematol Oncol. 2012 Jun;30(2):76-81. doi: 10.1002/hon.986. Epub 2011 Mar 8.

PMID:
21387357
14.

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.

Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ.

Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3.

15.

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Mistry H, Nduka C, Connock M, Colquitt J, Mantopoulos T, Loveman E, Walewska R, Mason J.

Pharmacoeconomics. 2018 Apr;36(4):399-406. doi: 10.1007/s40273-017-0599-9. Review.

16.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

17.

Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.

Meers S, Selleslag D, Potier H, Glasmacher A, Mineur P, Voelter V.

Curr Med Res Opin. 2015 Jan;31(1):35-42. doi: 10.1185/03007995.2014.972499. Epub 2014 Oct 17.

PMID:
25317956
18.

Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.

Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A.

Health Technol Assess. 2010 May;14 Suppl 1:55-62. doi: 10.3310/hta14Suppl1/08. Review.

19.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

20.

Sorafenib for the treatment of advanced hepatocellular carcinoma.

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D.

Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03. Review.

Supplemental Content

Support Center